Otologic Pharmaceutics

About:

Otologic Pharmaceutics, Inc. is a development stage pharmaceutical company formed specifically to commercialize promising technologies.

Website: http://www.otologicpharmaceutics.com

Top Investors: Oklahoma Medical Research Foundation, i2E, Accele Venture Partners

Description:

Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders. OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.

Total Funding Amount:

$4.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oklahoma City, Oklahoma, United States

Founded Date:

2009-01-01

Contact Email:

dk(AT)otologicpharmaceutics.com

Founders:

David Karlman, Richard Kopke, Robert Floyd

Number of Employees:

1-10

Last Funding Date:

2014-04-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai